

## Quick Search

[Advanced Search](#)

Enter Title, Keywords, Authors, or DOI

Search

 Biochemistry  All Journals/WebsitePersonalize your experience: [Log In](#) | [Register](#) | [Cart](#)

## BIOCHEMISTRY

## Article

Characterization of the Interacting Domain of the HIV-1 Fusion Peptide with the Transmembrane Domain of the T-Cell Receptor<sup>†</sup>Tomer Cohen<sup>‡</sup>, Meirav Pevsner-Fischer<sup>§</sup>, Noam Cohen<sup>§</sup>, Irun R. Cohen<sup>§</sup> and Yechiel Shai\*<sup>‡</sup>  
Departments of Biological Chemistry and Immunology, the Weizmann Institute of Science, Rehovot 76100, Israel*Biochemistry*, 2008, 47 (16), pp 4826-4833

DOI: 10.1021/bi800100p

Publication Date (Web): April 1, 2008

Copyright © 2008 American Chemical Society

† This study was supported by the Israel Science Foundation to Y.S.

‡ Department of Biological Chemistry.

§ Department of Immunology.

\* To whom correspondence should be addressed: Department of Biological Chemistry, the Weizmann Institute of Science, Rehovot, 76100 Israel. Telephone: 972-8-9342712 . Fax: 972-9344112. E-mail:

[yechiel.shai@weizmann.ac.il](mailto:yechiel.shai@weizmann.ac.il)


## Abstract

 Full Text HTML Hi-Res PDF [885 KB] PDF w/ Links [289 KB]

## Figures

## References

## Article Tools

 Add to Favorites Download Citation Email a Colleague Permalink Rights & Permissions Citation Alerts

## SciFinder Links



## History


Published In Issue  
April 22, 2008Article ASAP  
April 01, 2008Received: January 18, 2008  
Revised: February 26, 2008

## Recommend &amp; Share

 CiteULike Delicious Digg This Facebook Newsvine

## Abstract

HIV infection is initiated by the fusion of the viral membrane with the target T-cell membrane. The HIV envelope glycoprotein, gp41, contains a fusion peptide (FP) in the N terminus that functions together with other gp41 domains to fuse the virion with the host cell membrane. We recently reported that FP co-localizes with CD4 and T-cell receptor (TCR) molecules, co-precipitates with TCR, and inhibits antigen-specific T-cell proliferation and pro-inflammatory cytokine secretion. Molecular dynamic simulation implicated an interaction between an  $\alpha$ -helical transmembrane domain (TM) of the TCR $\alpha$  chain (designated CP) and the  $\beta$ -sheet 5-13 region of the 16 N-terminal amino acids of FP (FP<sub>1-16</sub>). To correlate between the theoretical prediction and experimental data, we synthesized a series of mutants derived from the interacting motif GALFLGFLG stretch (FP<sub>5-13</sub>) and investigated them structurally and functionally. The data reveal a direct correlation between the  $\beta$ -sheet structure of FP<sub>5-13</sub> and its mutants and their ability to interact with CP and induce immunosuppressive activity; the phenylalanines play an important role. Furthermore, studies with fluorescently labeled peptides revealed that this interaction leads to penetration of the N terminus of FP and its active analogues into the hydrophobic core of the membrane. A detailed understanding of the molecular interactions mediating the immunosuppressive activity of the FP<sub>5-13</sub> motif should facilitate evaluating its contribution to HIV pathology and its exploitation as an immunotherapeutic tool.



Enveloped viruses require a fusion of the viral membrane with the cellular membrane in the initial step of infection. The process of fusing the HIV membrane with the target T-cell membrane is catalyzed by the HIV glycoprotein gp41, which comprises several functional domains that contribute to the fusion process (1-5). Among them, the 33 residues at the N terminus (the fusion peptide, FP<sub>1-33</sub>) is of great importance (1, 3, 6-10) (Figure 1). Two different domains were identified within FP<sub>1-33</sub>: the 16 amino acid long hydrophobic stretch (FP<sub>1-16</sub>) in the N terminus that inserts into the host cell membrane and the C-terminus

hydrophilic region that lies parallel to the cell surface (11-14).




Figure 1. HIV-1 gp41 extracellular domain. A cartoon showing functional regions within the extracellular portion of gp41 (amino acids 512–684).

During the initial step of the membrane fusion process, FP<sub>1-16</sub> anchors gp41 to the target membrane. In the next step, conformational changes of gp41 bridge the gap between the opposing membranes and eventually complete the fusion process (5, 15-17). In an attempt to better understand the interaction of FP with T-cell membranes, we synthesized peptides that resemble or mimic the regions of the putative fusion peptide and investigated their interaction with T cells (18). The data revealed that FP co-localizes with CD4 and TCR molecules and co-precipitates with T-cell receptor  $\alpha$  subunit (TCR $\alpha$ ).<sup>1</sup> This interaction inhibits antigen-specific T-cell proliferation and pro-inflammatory cytokine secretion *in vitro*, leading to T-cell immunosuppression, which might function to suppress the HIV-specific immunity. In addition, it facilitates the spread of HIV to uninfected cells (18). We have also shown that this immunosuppressive activity of FP could be exploited as an immunotherapeutic tool by reducing the clinical signs of the experimental autoimmune T-cell-mediated disease adjuvant arthritis (AA) (18).

1

Abbreviations: ATR-FTIR, attenuated total reflectance Fourier transform infrared; CP, core peptide; FP, fusion peptide; LUV, large unilamellar vesicle; PC, phosphatidylcholine; TM, transmembrane; TCR $\alpha$ , T-cell receptor  $\alpha$  subunit; RP-HPLC, reverse-phase high-performance liquid chromatography.

The contribution of the different regions of FP to membrane fusion has been previously well-characterized (1, 5, 19-22). However, their role in the immunosuppressive activity of FP is still unknown. Recently, we used molecular dynamic simulation to identify the TCR/FP<sub>1-33</sub> interaction motif at the molecular level, providing a 3D model of the TCR/FP complex structure, and reported that the FP<sub>5-13</sub> region might play a role in the TCR/FP interaction (23).

In this study, we examined the contribution of the amino acids and the structural requirements of this highly conserved and hydrophobic GALFLGFLG stretch (FP<sub>5-13</sub>) by synthesizing and investigating its mutants (Table 1). Our data reveal that the FP<sub>5-13</sub> region is a conserved motif, in which phenylalanines significantly contribute to its function and  $\beta$ -sheet conformation. This structure is important for the interaction with TCR $\alpha$  TM (designated here CP) to induce immunosuppressive activity. Importantly, a similar  $\beta$ -sheet structure has also been implicated as the fusion-active conformation of FP under similar conditions. Note however that previous structural characterization of the FP has revealed contradictory data;  $\alpha$  helix or  $\beta$  structure (3, 6, 8, 9, 14, 24-39). This apparent dichotomy may be explained by structural plasticity, which serves a specific purpose during the fusion process. The  $\alpha$ -helical structure is more stabilized at low peptide/lipid molar ratios, whereas the  $\beta$ -sheet structure was implicated at higher peptide/lipid molar ratios. A detailed understanding of the molecular interactions mediating the immunosuppressive activity of the FP<sub>5-13</sub> motif should facilitate the evaluation of its contribution to HIV pathology and its exploitation as an immunotherapeutic tool.

Table 1. Designations and Sequences of the Peptides Investigated in This Study<sup>a</sup>

designation	sequence
FP <sub>1-16</sub>	A V G I G A L F L G F L G A A G
FP <sub>5-13</sub>	G A L F L G F L G
FP <sub>5-13</sub> FFxGG	G A L <b>G</b> L G <b>G</b> L G
FP <sub>5-13</sub> LLxGG	G A L F <b>G</b> G F <b>G</b> G
FP <sub>5-13</sub> FFxVV	G A L <b>V</b> L G <b>V</b> L G
FP <sub>5-13</sub> LLxVV	G A L F <b>V</b> G F <b>V</b> G

FP <sub>5-13</sub> AAAA	G A L <b>A</b> <b>A</b> G <b>A</b> <b>A</b> G
CP	G L R I L L L K V

a Substituted amino acids are in bold and underlined.

b The sequence of CP was taken from Manolios and co-workers (56).

## Experimental Procedures

### Materials

Rink amide MBHA resin and 9-fluorenylmethoxycarbonyl (Fmoc) amino acids were purchased from Calbiochem-Novabiochem AG (Switzerland). Other reagents used for peptide synthesis include *N,N*-diisopropylethylamine (DIEA, Aldrich), dimethylformamide, dichloromethane, and piperidine (Biolab, IL). Egg phosphatidylcholine (PC) was purchased from Lipid Products (South Nutfield, U.K.). 4-Chloro-7-nitrobenz-2-oxa-1,3-diazole fluoride (NBD-F) was purchased from Molecular Probes (Junction City, OR). The myelin oligodendrocyte glycoprotein (MOG) p35-55 antigen used for the specific activation of the T-cell line was synthesized using the F-MOC technique with an automatic multiple peptide synthesizer (AMS 422, ABIMED, Langenfeld, Germany). The Hamster antimouse anti-CD3 antibody was collected by trichloroacetic acid (TCA) precipitation from 2C11 hybridoma supernatant.

### Peptide Synthesis and Fluorescent Labeling

Peptides were synthesized using the F-moc solid-phase method on Rink amide resin (0.68 mequiv), as previously described (10). The synthetic peptides were purified (greater than 98% homogeneity) by reverse-phase high-performance liquid chromatography (RP-HPLC) on a C4 column using a linear gradient of 30-70% acetonitrile in 0.1% trifluoroacetic acid (TFA) for 40 min. The peptides were subjected to amino acid and mass spectrometry analysis to confirm their composition. To avoid aggregation of the peptides prior to their use in the cell-culture assays, the stock solutions of the concentrated peptides were maintained in dimethyl sulfoxide (DMSO). The final concentration of DMSO in each experiment was lower than 0.25% (vol/vol) and had no effect on the system under investigation. For fluorescent labeling, resin-bound peptides were treated with NBD-F (2-fold excess) dissolved in dimethyl formamide (DMF), leading to the formation of resin-bound N-terminal NBD peptides (40). After 1 h, the resins were washed thoroughly with DMF and then with methylene chloride, dried under nitrogen flow, and then cleaved for 3 h with 95% TFA, 2.5% H<sub>2</sub>O, and 2.5% triethylsilane. The labeled peptides were purified on a RP-HPLC C4 column as described above. Unless stated otherwise, stock solutions of concentrated peptides were maintained in DMSO to avoid aggregation of the peptides prior to use.

### Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) Spectroscopy

Spectra were obtained with a Bruker equinox 55 FTIR spectrometer equipped with a deuterated triglyceride sulfate (DTGS) detector, coupled with an ATR device. For each spectrum, 150 scans were collected, with a resolution of 4 cm<sup>-1</sup>. Samples were prepared as described (41). Briefly, lipids alone or with a peptide were deposited on a ZnSe horizontal ATR prism (80 × 7 mm). Before the sample was prepared, the trifluoroacetate (CF<sub>3</sub>COO<sup>-</sup>) counterions, which strongly associate with the peptide, were replaced by chloride ions through several washings in 0.1 M HCl and lyophilization. This eliminated the strong C=O stretching absorption band near 1673 cm<sup>-1</sup> (42). Peptides were dissolved in MeOH, which was chosen over DMSO, used in the lipid mixing experiments, because MeOH evaporates readily and is a suitable solvent for the lipids. Lipids were dissolved in a 1:2 MeOH/CHCl<sub>3</sub> mixture. Lipid-peptide mixtures at a 200:1 molar ratio or lipids alone with the corresponding volume of methanol were spread with a Teflon bar on the ZnSe prism. The solvents were eliminated by drying under vacuum for 15 min. Pure phospholipid spectra were subtracted to yield the difference spectra. The background for each spectrum was a clean ZnSe prism. The samples were hydrated by introducing an excess of deuterium oxide (<sup>2</sup>H<sub>2</sub>O) into a chamber placed on top of the ZnSe prism in the ATR casting and incubating for 5 min before acquiring the spectra. Hydrogen/deuterium exchange was considered complete because of the complete shift of the amide II band. Any contribution of <sup>2</sup>H<sub>2</sub>O vapor to the absorbance spectra near the amide I peak region was eliminated by subtracting the spectra of pure lipids equilibrated with <sup>2</sup>H<sub>2</sub>O under the same conditions.

### ATR-FTIR Data Analysis

To resolve overlapping bands, we processed spectra using PEAKFIT (Jandel Scientific, San Rafael, CA) software. Fourth-derivative spectra were calculated to identify the positions of the component bands in the spectra. These wavenumbers were used as initial parameters for curve fitting with Gaussian component peaks. Positions, bandwidths, and amplitudes of the peaks were varied until a good agreement between the calculated sum of all components and the experimental spectra was achieved ( $r^2 > 0.997$ ) under the following constraints: (i) the resulting bands shifted by no more than  $2\text{ cm}^{-1}$  from the initial parameters, and (ii) all of the peaks had reasonable half-widths ( $<20\text{--}25\text{ cm}^{-1}$ ). The relative amounts of the different secondary-structure elements were estimated by dividing the areas of individual peaks assigned to a particular secondary structure by the whole area of the resulting amide I band (43).

#### Preparation of Large Unilamellar Vesicles (LUVs)

Thin films of PC were generated after dissolving the lipids in a 2:1 (v/v) mixture of  $\text{CHCl}_3/\text{MeOH}$  and drying them under a stream of nitrogen gas while rotating them. The films were lyophilized overnight, sealed with argon gas to prevent oxidation of the lipids, and stored at  $-20\text{ }^\circ\text{C}$ . Before the experiments, films were suspended in the appropriate buffer and vortexed for 1.5 min. The lipid suspension underwent five cycles of freezing–thawing and extrusion through polycarbonate membranes with 1 and  $0.1\text{ }\mu\text{m}$  diameter pores to create LUVs.

#### Fluorescence Measurements of NBD-Labeled Peptides

The fluorescence experiments were performed using NBD-labeled peptides. Fluorescence spectra were obtained at room temperature, with excitation set at  $467\text{ nm}$  (10 nm slit) and emission scan at  $500\text{--}600\text{ nm}$  (10 nm slits). In a typical experiment, a NBD-labeled peptide was added first from a stock solution in DMSO [final concentration of  $0.5\text{ }\mu\text{M}$  and a maximum of 0.25% (v/v) DMSO] to a dispersion of PC LUV ( $100\text{ }\mu\text{M}$ ) in PBS. This was followed by the addition of unlabeled CP in several sequential doses ranging from  $0.125$  to  $1.5\text{ }\mu\text{M}$  (stock in DMSO). Fluorescence spectra were obtained before and after the addition of CP. The fluorescence values were corrected by subtracting the corresponding blank (buffer with the same vesicle concentration).

#### T-Cell Activation and Proliferation

T-cells were plated onto round 96-well plates in medium containing RPMI-1640 supplemented with 2.5% fetal calf serum (FCS), 100 units/mL penicillin,  $100\text{ }\mu\text{g/mL}$  streptomycin,  $50\text{ }\mu\text{M}$  2-mercaptoethanol, and  $2\text{ mM}$  L-glutamine. We used  $12 \times 10^4$  cells of the T-cell line specific to MOG p35-55,  $5 \times 10^5$  irradiated ( $3000\text{ rad}$ ) spleen cells (APC), and  $10\text{ }\mu\text{g/mL}$  of MOG p35-55 were added to each well. In addition, different fusion peptide derivatives were added. Each determination was made at least in triplicate.

For some experiments, T cells were activated with immobilized anti-CD3 antibodies. After 72 h, at  $37\text{ }^\circ\text{C}$  in a 7.5%  $\text{CO}_2$  humidified atmosphere, the T-cells were pulsed with  $1\text{ }\mu\text{Ci}$  ( $\text{H}^3$ ) thymidine, with a specific activity of  $5.0\text{ Ci/mmol}$ , for 7 h, and ( $\text{H}^3$ ) thymidine incorporation was measured using a 96-well plate B counter. The mean counts per minute (cpm)  $\pm$  standard error was calculated for each triplicate or quadruplicate. The results of T-cell proliferation experiments are shown as the percentage of T-cell proliferation inhibition triggered by the antigen in the absence of FP.

#### Mice

C57BL/6J mice were purchased from Harlan Olac (Bicester, U.K.). The mice were maintained in a specific pathogen-free facility and were used according to the guidelines and under the supervision of the animal welfare committee.

## Results

#### FP<sub>5-13</sub> Inhibits T-Cell Proliferation *in Vitro*

Recently, we have shown, using molecular dynamic simulation of the  $\text{TCR}\alpha\text{--TM/FP}$  complex, that the FP<sub>5-13</sub> region is the interacting motif that binds to the  $\text{TCR}\alpha\text{--TM}$  domain and interferes with T-cell activation (23). To investigate the underlying parameters within FP<sub>5-13</sub> responsible for this interaction, we synthesized a series of FP<sub>5-13</sub> amino-acid-substituted analogues (Table 1). In the first set of analogues, we replaced the two phenylalanines at positions 8 and 10 or

the two leucines at positions 9 and 12 with the small-sized and nonhydrophobic amino acid glycine (designated FP<sub>5-13</sub> FFxGG and FP<sub>5-13</sub> LLxGG, respectively). In the second series of derivatives, we substituted the same amino acids with the hydrophobic amino acid valine (designated FP<sub>5-13</sub> FFxVV and FP<sub>5-13</sub> LLxVV, respectively). We then incubated each peptide in the presence of MOG p35-55 antigen with a T-cell line that is specific to MOG p35-55 and determined their proliferative response to the peptides after 3 days of incubation, using a H<sup>3</sup>-thymidine uptake assay. MOG p35-55 is known to induce strong proliferative responses and cytokine release from this specific T-cell line. Figure 2 shows the inhibiting percentage caused by FP<sub>5-13</sub> and its amino-acid-substituted analogues. FP<sub>5-13</sub> inhibits ~45% T-cell proliferation response *in vitro*. However, practically no activity was observed when the two Phe residues were substituted, whereas substitution of Leu caused a less dramatic loss of activity. The FP<sub>5-13</sub> derivative, in which both Phe and Leu were replaced with alanine (FP<sub>5-13</sub> AAAAA), was used as a negative control, because we replaced the entire motif and found very low/basal inhibitory activity.




Figure 2. Inhibition of T-cell proliferation by the peptides. T-cells were activated with the MOG 35-55 peptide and APC in the presence of FP<sub>5-13</sub> and its derivatives (25 µg/mL), and the proliferative responses were assayed. The data are presented as mean inhibitions + SE ( $n = 3$  or more). The uninhibited T-cell proliferative responses were  $14301 \pm 430$  cpm. The background proliferation in the absence of antigen was  $213 \pm 44$  cpm. (\*) Inhibitory percentage of FP<sub>5-13</sub> was significantly more than any derivative ( $p < 0.05$ ). (\*\*) Inhibitory percentage of FP<sub>5-13</sub> LLxVV was significantly higher than the FP<sub>5-13</sub> FFxVV derivative ( $p < 0.05$ ).

The inhibitory effects of FP<sub>5-13</sub> and its analogues on antigen-triggered proliferation was not due to cell death, because cells incubated with FP<sub>5-13</sub> and its derivatives, or a control, in which PBS was added, showed the same survival in culture (data not shown).

### FP<sub>5-13</sub> Does Not Inhibit T-Cell Activation Induced by Antibodies to CD3

To determine whether FP<sub>5-13</sub> can also inhibit T-cell activation other than that induced by APC presentation of specific antigen, we tested the effect of FP<sub>5-13</sub> on T-cell activation induced by a mitogenic monoclonal antibody to CD3. FP<sub>5-13</sub>, similar to the full-length FP<sub>1-33</sub> (18), did not inhibit the activation of T-cells by mitogenic anti-CD3 (Figure 3). Mitogenic anti-CD3 antibodies activate CD3 signaling regardless of the presence or absence of TCR (44). These findings support our assumption that FP<sub>5-13</sub> inhibits T-cell activation by interfering with TCR/CD3 crosstalk similarly to the full-length FP<sub>1-33</sub>.




Figure 3. Noninhibitory effect of FP<sub>5-13</sub> toward T-cell activation induced by antibodies to CD3. T-cells were activated with 1 µg/mL anti-CD3 and APC in the presence of different FP<sub>5-13</sub> concentrations, and the proliferative responses were assayed.

### Changes in the Environment of FP<sub>5-13</sub> and Its Derivatives upon the Addition of CP Correlate with Biological Activity

NBD moiety can facilitate the determination of the environment of a NBD-labeled peptide in its membrane-bound state, because NBD fluorescence intensity is sensitive to the dielectric constant of its surroundings. This probe has already been used in many polarity and binding experiments (2, 45, 46). The fluorescence emission spectra of the NBD-labeled FP<sub>5-13</sub> and its derivatives were measured in the presence of PC LUV alone and in the presence of several sequential doses of unlabeled CP ranging from 0.125 to 1.5 µM. All NBD-labeled peptides exhibited very low-fluorescence signals in the presence of PC LUV alone. However, when the unlabeled CP was added, the fluorescence emission maxima of NBD-FP<sub>5-13</sub> increased sharply, concomitant with a blue shift (Figure 4A). A significant increase in the fluorescence of NBD was also observed with NBD-FP<sub>5-13</sub> LLxVV and NBD-FP<sub>5-13</sub> LLxGG (parts E and F of Figure 4 and

Table 2.) Note that these three peptides could significantly inhibit T-cell proliferation. The other derivatives did not exhibit significant changes in their fluorescence intensity upon the addition of CP (parts B–D of Figure 4 and Table 2). These results indicate that FP<sub>5-13</sub> specifically recognizes CP, and because of this interaction, FP changes its environment probably by penetrating into the lipidic environment of the membrane.




Figure 4. Changes in the environment of membrane-bound NBD-labeled FP<sub>5-13</sub> and its derivatives upon the addition of CP. The fluorescence experiments were performed using NBD-labeled FP<sub>5-13</sub> and its derivatives. Fluorescence spectra were obtained at room temperature, with excitation set at 467 nm (10 nm slit) and an emission scan at 500–600 nm (10 nm slits). In a typical experiment, a NBD-labeled peptide was added first to a dispersion of PC LUV (100 μM) in PBS. This was followed by the addition of an unlabeled CP peptide in several sequential doses. Fluorescence spectra were obtained in three different NBD-labeled peptides/CP ratio ranging from 1:0 to 1:3 (from the bottom to the top). NBD–FP<sub>5-13</sub> and NBD–FP<sub>5-13</sub> LLxVV (A and F, respectively) exhibited blue shifts concomitant with an increase in their fluorescence intensities around 530 nm, which indicates an environmental change of the labeled peptide. On the other hand, the other derivatives, FP<sub>5-13</sub> AAAAA, FP<sub>5-13</sub> FFxGG, FP<sub>5-13</sub> FFxVV, and FP<sub>5-13</sub> LLxGG (B, C, D, and E, respectively), did not exhibit significant changes in their fluorescence intensity.

**Table 2. Changes in the Environment of Membrane-Bound NBD-Labeled FP5-13 and Its Derivatives upon the Addition of CP<sup>a</sup>**

FP <sub>5-13</sub> LLxVV	FP <sub>5-13</sub> LLxGG	FP <sub>5-13</sub> FFxVV	FP <sub>5-13</sub> FFxGG	FP <sub>5-13</sub> AAAA	FP <sub>5-13</sub>	peptides ratio
0	0	0	0	0	54	1:0
70	15	37	106	21	227	1:1
165	119	70	175	61	337	1:2
347	250	116	228	85	437	1:3

<sup>a</sup> Fluorescence spectra were obtained at room temperature, with excitation set at 467 nm (10 nm slit) and the emission values at ~535 nm. Fluorescence spectra were obtained in three different NBD-labeled peptides/CP ratio ranging from 1:0 to 1:3.

**Structure of the Peptides in Phospholipid Membranes Determined Using FTIR Spectroscopy**  
The FTIR spectra of FP<sub>1-16</sub> and FP<sub>5-13</sub> and its derivatives in PC multibilayers are shown in Figure 5. FP<sub>1-16</sub> and FP<sub>5-13</sub> have similar spectra with major peak (~75%) characteristics of a β-sheet structure (parts G and A of Figure 5, respectively). In comparison, all of the analogues showed multiplex spectra, in which the percentages of the β-sheet structures are 40, 31, 16, 17, and 25%, for FP<sub>5-13</sub> LLxVV, FP<sub>5-13</sub> LLxGG, FP<sub>5-13</sub> FFxVV, FP<sub>5-13</sub> FFxGG, and FP<sub>5-13</sub> AAAAA, respectively. These data reveal that the extent of the β-sheet component in the structure of the peptides correlates with the ability of the peptides to inhibit T-cell proliferation.




Figure 5. ATR–FTIR spectra of deuterated amide I band (1600–1700 cm<sup>-1</sup>). FTIR spectra deconvolution of the fully deuterated amide I band (1600–1700 cm<sup>-1</sup>) of peptides in PC multibilayers. Second derivatives were calculated to identify the positions of the component bands in the spectra. The component peaks result from curve fitting using a Gaussian line shape. The sums of the fitted components are superimposed on the experimental amide I region spectra. Upper curves represent the experimental FTIR spectra, and lower curves represent the fitted components. Designations of peptides are indicated in each panel of the figure. ATR–FTIR spectra deconvolution showing a clear β-sheet structure (~75%) to FP<sub>5-13</sub> and FP<sub>1-16</sub> (A and G, respectively). Losses of β-sheet structure appear upon mutation within the FP<sub>5-13</sub> motif as shown in the ATR–FTIR spectra of FP<sub>5-13</sub> derivatives: B, FP<sub>5-13</sub> AAAAA (~25%); C, FP<sub>5-13</sub> FFxGG (~17%); D, FP<sub>5-13</sub> FFxVV (~16%); E, FP<sub>5-13</sub> LLxGG (~31%), and F, FP<sub>5-13</sub> LLxVV (~40%).

## Discussion

The data presented in this study strongly support the notion that the HIV-1 FP<sub>5-13</sub> region is the FP/TCR $\alpha$ -interacting motif. Its ability to inhibit T-cell proliferation in response to specific antigen is similar to that of the entire 16-mer fusion peptide. To understand the underlying parameters allowing this specific interaction, we synthesized and functionally and structurally analyzed a series of mutants derived from FP<sub>5-13</sub>. The data reveal two interesting findings that relate to this interaction: (i) the  $\beta$ -sheet structure is a biologically active structure; several studies have shown that a similar structure was implicated in its membrane fusion activity, and (ii) the interaction between FP and TCR $\alpha$ -TM causes an insertion of the N terminus of FP<sub>5-13</sub> and its biologically active analogues into the membrane.

### $\beta$ -Sheet Structure Is the Biologically Active Conformation of FP upon Its Binding to the TCR $\alpha$ -TM Domain

The FTIR studies (Figure 5) suggest that FP<sub>5-13</sub> needs to adopt a  $\beta$ -sheet conformation to interact with CP to exert immunosuppressive activity. In support of this, the data reveal that the order of the increased  $\beta$ -sheet structure of the peptides (Figure 5) correlates with the order of their increased potential to inhibit T-cell proliferation: FP<sub>5-13</sub> > FP<sub>5-13</sub> LLxVV > FP<sub>5-13</sub> LLxGG > FP<sub>5-13</sub> FFxVV  $\approx$  FP<sub>5-13</sub> FFxGG  $\approx$  FP<sub>5-13</sub> AAAA. The importance of the  $\beta$ -sheet structure for exerting biological activity is in agreement with the molecular dynamic simulations of the interaction between the entire FP and the TCR $\alpha$ -TM domain (23). It is important to mention that previous structural characterization of the FP has revealed seemingly paradoxical data:  $\alpha$  helix or  $\beta$  structure (3, 6, 8, 9, 14, 24-39). As indicated before, this apparent dichotomy may be explained by structural plasticity inherent in the FP based on its primary sequence given in Figure 1 (highly enriched in Gly and Ala). During the fusion event, both structures may be relevant and serve specific purposes.

In addition, the present data revealed a difference between the analogues in which the phenylalanines were replaced and those in which the leucines were replaced. In general, in comparison to the leucine-substituted analogues, substitution of the phenylalanines reduced the  $\beta$ -sheet component more (Figure 5), decreased the ability of the peptide to interact with CP (Figure 4), and inhibited T-cell proliferation (Figure 2). A possible explanation is that phenylalanine could create  $\pi$ - $\pi$  aromatic interactions. Such interactions are highly important in the protein stabilization and assembly processes outside the membrane (47, 48). In addition, recent reports showed that aromatic residues are involved in the dimerization of TM domains of membrane proteins and that the aromatic motif, aromatic-X-X-aromatic, contributes, although partially to specificity, in TM domain assembly (49). In support of this, molecular dynamic simulation of the interaction between CP and FP<sub>1-16</sub> resulted in an interaction between the phenylalanines from both regions (23). Note also that aromatic interactions play a role and act as a driving force in the creation of a  $\beta$ -sheet structure (50). Moreover, the gp41 protein forms trimers on the viral membrane (51), and FP itself oligomerizes in solution and in membranes (10, 37). It is therefore likely that phenylalanines and leucines are also required for this assembly, and therefore, the inhibitory effect of the peptides depends upon not only the interaction between FP and CP but also the interaction between several FP fragments needed for the assembly. The fusion peptide domain of the gp41 protein, which is highly conserved despite the frequent mutation of HIV-1 (52, 53), seems to be selected for its ability to inhibit T-cell proliferation.

### Interaction Between CP and FP Moves the N-Terminal of CP toward the Hydrophobic Core of the Membrane

We labeled the N terminus of FP<sub>5-13</sub> and its analogues with NBD, let them interact with PC membranes, and followed their fluorescence upon the addition of CP. The data revealed that the interaction between CP and FP<sub>5-13</sub> caused a change in the location of the N-terminal of FP<sub>5-13</sub> to a more hydrophobic environment, as indicated by the marked increase in the fluorescence of the NBD group (Figure 4 and Table 2). These data suggest that the binding of CP to FP<sub>5-13</sub> caused most likely conformational changes resulting in its insertion into the hydrophobic core of the membrane. It is reasonable to assume that this conformational change allows for the creation of hydrogen bonds between the TCR $\alpha$  polar residues and the carbonyl

atoms of the FP backbone that further stabilized the FP/TCR $\alpha$  complex inside the membrane (23). However, this model does not completely satisfy the energetic requirements of the hydrogen donor/acceptor atoms of the backbone between  $\alpha$  helix and the single  $\beta$  strand inside the membrane. Nevertheless, the gp41 protein forms trimers (51) on the viral membrane, and FP itself oligomerizes in solution (10, 37). This allows FP to adopt a  $\beta$ -sheet conformation and still satisfy the energy requirement for hydrogen bonds that would stabilize its interaction with  $\alpha$ -helix CP. Despite the fact that such interactions are unusual, they might be favored by the special features of intermolecular interactions within the membrane milieu (54, 55).

Similar experiments were performed with all of the analogues. Importantly, the extent of the increase in fluorescence (Figure 4 and Table 2) correlates with the increase in the  $\beta$ -sheet structure of the different peptides (Figure 5), as well as with their ability to inhibit T-cell proliferation (Figure 2). However, we cannot rule out the possibility that the environment of the NBD moiety is also affected by a direct interaction with CP, which causes an intermolecular organization of the membrane-bound peptide. In both cases, the change in fluorescence indicates an interaction between CP and the corresponding FP analogues.

In summary, our data suggest that FP<sub>5-13</sub> needs to adopt a  $\beta$ -sheet conformation for efficient interaction with CP to induce immunosuppressive activity. Furthermore, the drastic loss of the FP<sub>5-13</sub> activity can explain why it is highly conserved within the different HIV strains; this supports its highly specific interaction with the CP region.

#### Acknowledgment

Y.S. holds the Harold S. and Harriet B. Brady Professorial Chair in Cancer Research. I.R.C. is the Mauerberger Professor of Immunology at the Weizmann Institute of Science and the director of the Center for the Study of Emerging Diseases, Jerusalem.

#### References

This article references 56 other publications.

1. Freed, E. O., Myers, D. J., and Risser, R. 1990 Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41 *Proc. Natl. Acad. Sci. U.S.A.* 87 4650 4654 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
2. Frey, S., and Tamm, L. K. 1990 Membrane insertion and lateral diffusion of fluorescence-labelled cytochrome c oxidase subunit IV signal peptide in charged and uncharged phospholipid bilayers *Biochem. J.* 272 713 719 [[PubMed](#)], [[ChemPort](#)]
3. Gordon, L. M., Curtain, C. C., Zhong, Y. C., Kirkpatrick, A., Mobley, P. W., and Waring, A. J. 1992 The amino-terminal peptide of HIV-1 glycoprotein 41 interacts with human erythrocyte membranes: Peptide conformation, orientation and aggregation *Biochim. Biophys. Acta* 1139 257 274 [[PubMed](#)], [[ChemPort](#)]
4. White, J. M. 1992 Membrane fusion *Science* 258 917 924 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
5. Chan, D. C., Fass, D., Berger, J. M., and Kim, P. S. 1997 Core structure of gp41 from the HIV envelope glycoprotein *Cell* 89 263 273 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
6. Rafalski, M., Lear, J. D., and DeGrado, W. F. 1990 Phospholipid interactions of synthetic peptides representing the N-terminus of HIV gp41 *Biochemistry* 29 7917 7922 [[ACS Full Text](#)], [[PubMed](#)], [[ChemPort](#)]
7. Slepishkin, V. A., Andreev, S. M., Sidorova, M. V., Melikyan, G. B., Grigoriev, V. B., Chumakov, V. M., Grinfeldt, A. E., Manukyan, R. A., and Karamov, E. V. 1992 Investigation of human immunodeficiency virus fusion peptides. Analysis of interrelations between their structure and function *AIDS Res. Hum. Retroviruses* 8 9 18 [[PubMed](#)], [[ChemPort](#)]
8. Martin, I., Defrise-Quertain, F., Decroly, E., Vandenbranden, M., Brasseur, R., and Ruyschaert, J. M. 1993 Orientation and structure of the NH<sub>2</sub>-terminal HIV-1 gp41 peptide in fused and aggregated liposomes *Biochim. Biophys. Acta* 1145 124 133 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
9. Nieva, J. L., Nir, S., Muga, A., Goni, F. M., and Wilschut, J. 1994 Interaction of the HIV-1 fusion peptide with phospholipid vesicles: Different structural requirements for fusion and



leakage *Biochemistry* 33 3201 3209 [[ACS Full Text](#)], [[PubMed](#)], [[ChemPort](#)]

10. Kliger, Y., Aharoni, A., Rapaport, D., Jones, P., Blumenthal, R., and Shai, Y. **1997** Fusion peptides derived from the HIV type 1 glycoprotein 41 associate within phospholipid membranes and inhibit cell–cell fusion. Structure–function study *J. Biol. Chem.* 272 13496 13505 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
11. Blumenthal, R., Schoch, C., Puri, A., and Clague, M. J. **1991** A dissection of steps leading to viral envelope protein-mediated membrane fusion *Ann. N.Y. Acad. Sci.* 635 285 296 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
12. Suarez, T., Nir, S., Goni, F. M., Saez-Cirion, A., and Nieva, J. L. **2000** The pre-transmembrane region of the human immunodeficiency virus type-1 glycoprotein: A novel fusogenic sequence *FEBS. Lett.* 477 145 149 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
13. Eband, R. M. **2003** Fusion peptides and the mechanism of viral fusion *Biochim. Biophys. Acta* 1614 116 121 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
14. Peisajovich, S. G., Eband, R. F., Pritsker, M., Shai, Y., and Eband, R. M. **2000** The polar region consecutive to the HIV fusion peptide participates in membrane fusion *Biochemistry* 39 1826 1833 [[ACS Full Text](#)], [[PubMed](#)], [[ChemPort](#)]
15. Pombourios, P., Wilson, K. A., Center, R. J., El Ahmar, W., and Kemp, B. E. **1997** Human immunodeficiency virus type 1 envelope glycoprotein oligomerization requires the gp41 amphipathic  $\alpha$ -helical/leucine zipper-like sequence *J. Virol.* 71 2041 2049 [[PubMed](#)], [[ChemPort](#)]
16. Weissenhorn, W., Dessen, A., Calder, L. J., Harrison, S. C., Skehel, J. J., and Wiley, D. C. **1999** Structural basis for membrane fusion by enveloped viruses *Mol. Membr. Biol.* 16 3 9 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
17. Peisajovich, S. G., and Shai, Y. **2003** Viral fusion proteins: Multiple regions contribute to membrane fusion *Biochim. Biophys. Acta* 1614 122 129 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
18. Quintana, F. J., Gerber, D., Kent, S. C., Cohen, I. R., and Shai, Y. **2005** HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation *J. Clin. Invest.* 115 2149 2158 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
19. Freed, E. O., Delwart, E. L., Buchschacher, G. L., Jr., and Panganiban, A. T. **1992** A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity *Proc. Natl. Acad. Sci. U.S.A.* 89 70 74 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
20. Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J., and Wiley, D. C. **1997** Atomic structure of the ectodomain from HIV-1 gp41 *Nature* 387 426 430 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
21. Kliger, Y., Peisajovich, S. G., Blumenthal, R., and Shai, Y. **2000** Membrane-induced conformational change during the activation of HIV-1 gp41 *J. Mol. Biol.* 301 905 914 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
22. Kliger, Y., Gallo, S. A., Peisajovich, S. G., Munoz-Barroso, I., Avkin, S., Blumenthal, R., and Shai, Y. **2001** Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage *J. Biol. Chem.* 276 1391 1397 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
23. Bloch, I., Quintana, F. J., Gerber, D., Cohen, T., Cohen, I. R., and Shai, Y. **2007** T-cell inactivation and immunosuppressive activity induced by HIV gp41 via novel interacting motif *FASEB J.* 21 393 401 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
24. Mobley, P. W., Waring, A. J., Sherman, M. A., and Gordon, L. M. **1999** Membrane interactions of the synthetic N-terminal peptide of HIV-1 gp41 and its structural analogs *Biochim. Biophys. Acta* 1418 1 18 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
25. Martin, I., Schaal, H., Scheid, A., and Ruyschaert, J. M. **1996** Lipid membrane fusion induced by the human immunodeficiency virus type 1 gp41 N-terminal extremity is determined by its orientation in the lipid bilayer *J. Virol.* 70 298 304 [[PubMed](#)], [[ChemPort](#)]
26. Gordon, L. M., Lee, K. Y., Lipp, M. M., Zasadzinski, J. A., Walther, F. J., Sherman, M. A., and Waring, A. J. **2000** Conformational mapping of the N-terminal segment of surfactant protein B in lipid using  $^{13}\text{C}$ -enhanced Fourier transform infrared spectroscopy *J. Pept. Res.* 55 330 347 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
27. Gordon, L. M., Mobley, P. W., Pilpa, R., Sherman, M. A., and Waring, A. J. **2002** Conformational mapping of the N-terminal peptide of HIV-1 gp41 in membrane environments using  $^{13}\text{C}$ -enhanced Fourier transform infrared spectroscopy *Biochim. Biophys. Acta* 1559 96 120 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
28. Gordon, L. M., Mobley, P. W., Lee, W., Eskandari, S., Kaznessis, Y. N., Sherman, M. A., and Waring, A. J. **2004** Conformational mapping of the N-terminal peptide of HIV-1 gp41 in lipid detergent and aqueous environments using  $^{13}\text{C}$ -enhanced Fourier transform

- infrared spectroscopy *Protein Sci.* 13 1012 1030 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
29. Pereira, F. B., Goni, F. M., Muga, A., and Nieva, J. L. 1997 Permeabilization and fusion of uncharged lipid vesicles induced by the HIV-1 fusion peptide adopting an extended conformation: Dose and sequence effects *Biophys. J.* 73 1977 1986 [[PubMed](#)], [[ChemPort](#)]
  30. Curtain, C., Separovic, F., Nielsen, K., Craik, D., Zhong, Y., and Kirkpatrick, A. 1999 The interactions of the N-terminal fusogenic peptide of HIV-1 gp41 with neutral phospholipids *Eur. Biophys. J.* 28 427 436 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
  31. Yang, J., Gabrys, C. M., and Weliky, D. P. 2001 Solid-state nuclear magnetic resonance evidence for an extended  $\beta$  strand conformation of the membrane-bound HIV-1 fusion peptide *Biochemistry* 40 8126 8137 [[ACS Full Text](#)], [[PubMed](#)], [[ChemPort](#)]
  32. Yang, R., Yang, J., and Weliky, D. P. 2003 Synthesis, enhanced fusogenicity, and solid state NMR measurements of cross-linked HIV-1 fusion peptides *Biochemistry* 42 3527 3535 [[ACS Full Text](#)], [[PubMed](#)], [[ChemPort](#)]
  33. Yang, J., and Weliky, D. P. 2003 Solid-state nuclear magnetic resonance evidence for parallel and antiparallel strand arrangements in the membrane-associated HIV-1 fusion peptide *Biochemistry* 42 11879 11890 [[ACS Full Text](#)], [[PubMed](#)], [[ChemPort](#)]
  34. Yang, R., Prorok, M., Castellino, F. J., and Weliky, D. P. 2004 A trimeric HIV-1 fusion peptide construct which does not self-associate in aqueous solution and which has 15-fold higher membrane fusion rate *J. Am. Chem. Soc.* 126 14722 14723 [[ACS Full Text](#)], [[PubMed](#)], [[ChemPort](#)]
  35. Jaroniec, C. P., Kaufman, J. D., Stahl, S. J., Viard, M., Blumenthal, R., Wingfield, P. T., and Bax, A. 2005 Structure and dynamics of micelle-associated human immunodeficiency virus gp41 fusion domain *Biochemistry* 44 16167 16180 [[ACS Full Text](#)], [[PubMed](#)], [[ChemPort](#)]
  36. Yang, J., Prorok, M., Castellino, F. J., and Weliky, D. P. 2004 Oligomeric  $\beta$ -structure of the membrane-bound HIV-1 fusion peptide formed from soluble monomers *Biophys. J.* 87 1951 1963 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
  37. Sackett, K., and Shai, Y. 2005 The HIV fusion peptide adopts intermolecular parallel  $\beta$ -sheet structure in membranes when stabilized by the adjacent N-terminal heptad repeat: A  $^{13}\text{C}$  FTIR study *J. Mol. Biol.* 350 790 805 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
  38. Zheng, Z., Yang, R., Bodner, M. L., and Weliky, D. P. 2006 Conformational flexibility and strand arrangements of the membrane-associated HIV fusion peptide trimer probed by solid-state NMR spectroscopy *Biochemistry* 45 12960 12975 [[ACS Full Text](#)], [[PubMed](#)], [[ChemPort](#)]
  39. Li, Y., and Tamm, L. K. 2007 Structure and plasticity of the human immunodeficiency virus gp41 fusion domain in lipid micelles and bilayers *Biophys. J.* 93 876 885 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
  40. Gerber, D., and Shai, Y. 2000 Insertion and organization within membranes of the  $\delta$ -endotoxin pore-forming domain, helix 4-loop-helix 5, and inhibition of its activity by a mutant helix 4 peptide *J. Biol. Chem.* 275 23602 23607 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
  41. Gazit, E., Miller, I. R., Biggin, P. C., Sansom, M. S., and Shai, Y. 1996 Structure and orientation of the mammalian antibacterial peptide cecropin P1 within phospholipid membranes *J. Mol. Biol.* 258 860 870 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
  42. Surewicz, W. K., Mantsch, H. H., and Chapman, D. 1993 Determination of protein secondary structure by Fourier transform infrared spectroscopy: A critical assessment *Biochemistry* 32 389 394 [[ACS Full Text](#)], [[PubMed](#)], [[ChemPort](#)]
  43. Jackson, M., and Mantsch, H. H. 1995 The use and misuse of FTIR spectroscopy in the determination of protein structure *Crit. Rev. Biochem. Mol. Biol.* 30 95 120 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
  44. Wang, X. M., Djordjevic, J. T., Kurosaka, N., Schibeci, S., Lee, L., Williamson, P., and Manolios, N. 2002 T-cell antigen receptor peptides inhibit signal transduction within the membrane bilayer *Clin. Immunol.* 105 199 207 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
  45. Rajarathnam, K., Hochman, J., Schindler, M., and Ferguson-Miller, S. 1989 Synthesis, location, and lateral mobility of fluorescently labeled ubiquinone 10 in mitochondrial and artificial membranes *Biochemistry* 28 3168 3176 [[ACS Full Text](#)], [[PubMed](#)], [[ChemPort](#)]
  46. Rapaport, D., and Shai, Y. 1991 Interaction of fluorescently labeled pardaxin and its analogues with lipid bilayers *J. Biol. Chem.* 266 23769 23775 [[PubMed](#)], [[ChemPort](#)]
  47. Serrano, L., Bycroft, M., and Fersht, A. R. 1991 Aromatic-aromatic interactions and protein stability. Investigation by double-mutant cycles *J. Mol. Biol.* 218 465 475 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
  48. Burley, S. K., and Petsko, G. A. 1985 Aromatic-aromatic interaction: A mechanism of

protein structure stabilization *Science* 229 23 28 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]

49. Sal-Man, N., Gerber, D., Bloch, I., and Shai, Y. **2007** Specificity in transmembrane helix–helix interactions mediated by aromatic residues *J. Biol. Chem.* 282 19753 19761 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
50. Aggeli, A., Bell, M., Boden, N., Keen, J. N., Knowles, P. F., McLeish, T. C., Pitkeathly, M., and Radford, S. E. **1997** Responsive gels formed by the spontaneous self-assembly of peptides into polymeric  $\beta$ -sheet tapes *Nature* 386 259 262 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
51. Center, R. J., Leapman, R. D., Lebowitz, J., Arthur, L. O., Earl, P. L., and Moss, B. **2002** Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface *J. Virol.* 76 7863 7867 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
52. de Jong, M. D., Schuurman, R., Lange, J. M., and Boucher, C. A. **1996** Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure *Antiviral Ther.* 1 33 41 [[PubMed](#)], [[ChemPort](#)]
53. Mayers, D. L. **1997** Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs *Am. J. Med.* 102 70 75 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
54. Fleming, K. G., and Engelman, D. M. **2001** Specificity in transmembrane helix–helix interactions can define a hierarchy of stability for sequence variants *Proc. Natl. Acad. Sci. U.S.A.* 98 14340 14344 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
55. Senes, A., Ubarretxena-Belandia, I., and Engelman, D. M. **2001** The  $\alpha$ -H $\cdots$ O hydrogen bond: A determinant of stability and specificity in transmembrane helix interactions *Proc. Natl. Acad. Sci. U.S.A.* 98 9056 9061 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]
56. Manolios, N., Collier, S., Taylor, J., Pollard, J., Harrison, L. C., and Bender, V. **1997** T-cell antigen receptor transmembrane peptides modulate T-cell function and T cell-mediated disease *Nat. Med.* 3 84 88 [[CrossRef](#)], [[PubMed](#)], [[ChemPort](#)]